Welcome to the 569th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.
The highlights of this week's edition are randomised controlled trials on methylprednisolone for heart surgery in infants & blood pressure control after endovascular thrombectomy for acute ischaemic stroke; systematic reviews and meta analyses on coronary angiography after cardiac arrest without ST-elevation myocardial infarction & respiratory system mechanics and outcomes in mechanically ventilated patients with COVID-19-related ARDS; and observational studies on treatment time and in-hospital mortality among patients with ST-segment elevation myocardial infarction & the association between preoperative hemodialysis timing and postoperative mortality in patients with end-stage kidney disease.
There are also guidelines on cardiopulmonary resuscitation and emergency cardiovascular care & artificial liver and blood purification; narrative reviews on the pathophysiology of fluid administration in critically ill patients & kidney dysfunction after traumatic brain injury; editorials on ICU scoring systems & difficult airway management; and commentaries on collaboration between pathologists and intensivists to understand (not just) coronavirus disease & heterogeneity in pragmatic randomised trials; as well as correspondence on pathogen-specific perspectives of fluid therapy & informed consent in acute care research.
If you only have time to read one review article this week, try this one on advances in the staging and phenotyping of cardiogenic shock.
We believe no patient should suffer because their clinicians lack access to either the latest research findings or core clinical information. If you feel similarly, please join us as we build a key resource to serve the critical care community worldwide. Just reply to this email.
Registration for CCR23 is open.
You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. We are not-for-profit and make all our content free to view. Our aim is to share science for the benefit of all - please join us in this mission.
I hope you find this newsletter useful.
Until next week